Navigation Links
Cancer Risk After Kidney Transplant Unaffected by Type of Drug Treatment
Date:4/29/2010

Risk similar from all drugs used to prevent organ rejection, researchers find

THURSDAY, April 29 (HealthDay News) -- The type of drug treatment used to prevent organ rejection in kidney transplant patients doesn't affect cancer risk, a new study finds.

Kidney transplant patients are at increased risk for cancer, likely because of patients' long-term use of immunosuppressive drugs to prevent organ rejection. In this study, Australian researchers examined the incidence of cancer in 481 kidney transplant patients.

The patients had received one of three treatment regimens: azathioprine and prednisolone; cyclosporine monotherapy; or cyclesoporine monotherapy followed by a switch to azathioprine and prednisolone after three months.

In the 20 years after transplant, 226 patients developed at least one cancer, including 48 percent who developed skin cancer and 27 percent who developed non-skin cancer. None of the anti-rejection treatments had a greater effect than another on cancer timing or incidence.

The findings indicate that "any differences in cancer risk from these different treatments are unlikely to be clinically significant," said study author Martin Gallagher, of the George Institute for International Health in Australia.

He and his colleagues also found that kidney transplant recipients' increased risk of cancer is significantly influenced by certain characteristics at the time of transplant. For example, non-skin cancer is associated with increasing age and previous smoking history, while skin cancer is associated with increasing age, non-brown eye color, fairer skin, and a functioning transplant.

High-risk patients need to be monitored more closely and use preventive measures to protect against cancer, the researchers said.

The study appears in the April 29 issue of the Journal of the American Society of Nephrology.

More information

The National Kidney Foundation has more about reducing cancer risk after a kidney transplant.



-- Robert Preidt



SOURCE: American Society of Nephrology, news release, April 29, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cells programmed to cure and even prevent cancer
2. FDA Approval of new Prostate Treatment Shows Promise of Cancer Immunotherapy
3. Prostate Cancer Vaccine Gains FDA Approval
4. CXCR4: A new drug target in lung cancer
5. Best care for the oldest lung cancer patients
6. Curcumin nanoparticles open up resistant cancers
7. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
8. Breakthrough in Predicting Invasive Breast Cancer
9. Comparison of available breast cancer risk assessment tools shows room for improvement
10. Breakthrough method predicts risk of invasive breast cancer
11. Researchers attack stem cells that cause colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... ... Medicine recently spoke at a popular international aesthetics conference for medical professionals about ... restoring his patients’ health and his growing practice. , Dr. George K. ...
(Date:8/22/2017)... TX (PRWEB) , ... August 22, 2017 , ... Five Star Glass is new to ... provide repair and replacement of auto glass for most makes and models, in Grand Prairie, ... the USA. , They have been a family owned business for the past 40 ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that ... healthcare employers connect with physicians and advanced practitioners like nurse practitioners and ... in August through November of this year. The online career fairs will allow ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... announced that it has become the Official Technology Partner of North Country Region ... (Advanced Event Systems) volleyball software, along with providing sport management software to ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... WARSAW, Ind. , Aug. 7, 2017 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the third quarter of 2017. ... will be paid on or about October 27, 2017 to ... September 22, 2017.  Future declarations of dividends are subject to ...
Breaking Medicine Technology: